Table 3 Association between HOXA9 gene expression and patients' characteristics
From: Evaluation of the HOXA9 and MEIS1 genes as a potential biomarker in adult acute myeloid leukemia
HOXA9 low expression (n = 11) | HOXA9 over-expression (n = 80) | p value | |
|---|---|---|---|
Age (years) | 31 (20–57) | 34 (18–65) | 0.384 |
TLC (×103/mm3) | 29.7 (7–160) | 41(1–440) | 0.703 |
HB (gm/dl) | 7.8 (6.8–12.1) | 8 (2.3–13) | 0.716 |
Platelet count (×103/mm3) | 21 (8–297) | 35 (5–240) | 0.359 |
PB blast (%) | 50 (13–95) | 52 (0–98) | 0.990 |
BM blast (%) | 73 (39–97) | 70 (14–95) | 0.336 |
Sex | |||
Male | 9 (81.8%) | 41 (51.3%) | 0.103 |
Female | 2 (18.2%) | 39 (48.8%) | |
Hepatomegaly | |||
Positive | 5 (45.5%) | 22 (27.5%) | 0.292 |
Spleenomegaly | |||
Positive | 3 (27.3%) | 20 (25.0%) | 0.871 |
Lymphadenopathy | |||
Positive | 3 (27.3%) | 27 (33.8%) | 0.668 |
BM cellularity | |||
Hypercellular | 10 (90.9%) | 60 (75.0%) | 0.449 |
Hypocellular | 0 (0.0%) | 7 (8.8%) | |
Normocellular | 1 (9.1%) | 13 (16.3%) | |
FAB | |||
M1 | 3 (27.3%) | 8 (10.0%) | 0.532 |
M2 | 3 (27.3%) | 35 (43.8%) | |
M4 | 3 (27.3%) | 21 (26.3%) | |
M5 | 2 (18.2%) | 15 (18.8%) | |
M7 | 0 (0.0%) | 1 (1.3%) | |
MPO | |||
Positive | 11 (100.0%) | 77 (96.25%) | 1.00 |
CD13 | |||
Positive | 11 (100.0%) | 80(100.0%) | NA |
CD33 | |||
Positive | 11 (100.0%) | 80(100.0%) | NA |
CD14 | |||
Positive | 7 (63.6%) | 37 (46.3%) | 0.344 |
CD61 | |||
Positive | 0 (0.0%) | 1(1.3%) | 1.00 |
Aberrant IPT markers | |||
Normal | 7 (63.6%) | 66 (82.5%) | 0.218 |
Aberrant | 4 (36.4%) | 14 (17.5%) | |
IPT | |||
Monocytic | 1 (9.1%) | 6 (7.5%) | 0.977 |
Myeloid | 6 (54.5%) | 46 (57.5%) | |
Myelomonocytic | 4 (36.4%) | 27 (33.8%) | |
Megakaryoblasic | 0 (0.0%) | 1 (1.3%) | |
FLT3(ITD) | |||
Wild | 11 (100%) | 66 (82.5%) | 0.203 |
Mutant | 0 (0.0%) | 14 (17.5%) | |
Cytogenetic risk | |||
Favorable | 1 (9.1%) | 13 (16.3%) | 0.603 |
Intermediate | 7 (63.6%) | 54 (67.5%) | |
Adverse | 3 (27.3%) | 13 (16.3%) | |
Response to treatment | |||
CR | 8 (72.7%) | 60 (75.0%) | 0.871 |
No CR | 3 (27.3%) | 20 (25.0%) | |
Survival analysis | |||
Median OS | 11.070 | 11.400 | 0.799 |
Cumulative OS after 3 years | 15.9% | 30.4% | |
Median DFS | 9.230 | 16.800 | 0.264 |
Cumulative DFS after 3 years | 0.0% | 44.1% | |